1. Home
  2. Conferences
  3. TSCA Developments 2020
  4. programme

Agenda

**Note: timings are in EDT**

  1. Welcome and introduction

    Moderator:

    Terry Hyland Terry Hyland
    Senior Editor, North America, Chemical Watch News & Insight, Enhesa Product Intelligence
  2. Session one: Regulatory updates

  3. Keynote  Keynote: TSCA Updates from the EPA

    Alexandra Dapolito Dunn Alexandra Dapolito Dunn
    Partner, Baker Botts

  4. TSCA chemical data reporting (CDR) 2020: Something old, something new

    • Update on the current reporting window
    • Update on the small business definition
    Jeff Hafer Jeff Hafer
    Senior Regulatory Scientist, knoell USA, United States

  5. TSCA fees

    • Upcoming rulemaking on fee exemptions
    • Overview of self-identification process
    • Strategies for payment: How are consortia dividing up fees between participants?
    Lynn L. Bergeson Lynn L. Bergeson
    Managing Partner of Bergeson & Campbell, P.C. (B&C®) and President of The Acta Group, L.L.C. (Acta®), Bergeson & Campbell, USA

  6. Q&A

  7. TSCA new chemical programme

    • Changes under the LCSA
    • Their Impact on the Chemical Industry
    • Practical Considerations and Recommendations
    John J. Kowalski John J. Kowalski
    Regulatory Affairs Lead, UL Solutions, USA

  8. TSCA new chemical programme statistics and pre-manufacture notice (PMN) status

    • Programme statistics: update on PMN 'backlog' and EPA new chemical review efforts
    • A reflection on PMN submissions since the new higher fees took effect
    Devin Millions Devin Millions
    Managing Scientist, Exponent

  9. Q&A

  10. Chemical Watch platform and service demonstration

    Tassia Agatowski Tassia Agatowski
    Marketing Manager, Chemical Watch

  11. Break

  12. Session two: Risk management and evaluation

  13. A reflection on recent risk evaluations: NGO perspective

    Is the EPA risk evaluation process effectively protecting the public?

    • The impact of the SACC peer review process
    • Gaps in the EPA evaluations
    • Important policy and legal issues
    Bob Sussman Bob Sussman
    Principal, Sussman and Associates, United States

  14. Preview of emerging issues on the next 20 risk evaluations: Lessons learned from the first 10

    • Should we expect the EPA to issue test orders and make other efforts to fill data gaps? 
    • What role are industry consortia playing in this process?
    Herb Estreicher Herb Estreicher
    Partner, Keller and Heckman LLP, United States

  15. Q&A

  16. Session three: Confidential business information (CBI) under TSCA, enforcement and litigation

  17. CBI substantiation overview

    • Issues that could cause the EPA to drop a chemical identity confidentiality claim and what recourse companies have to stop this
    • An insight into CBI’s upfront substantiation requirements
    Erik Baptist Erik Baptist
    Partner, Wiley Rein LLP

  18. Enforcement and litigation issues including enforcement during the Covid-19 pandemic

    Sara Beth Watson Sara Beth Watson
    Counsel, Steptoe and Johnson LLP

  19. Q&A

  20. Break

  21. Session four: Stakeholder perspectives and outlooks

  22. Covid 19 – the impact of the coronavirus on TSCA

  23. Reflections on four years of implementing the Lautenberg Amendments: a former EPA insider’s perspective and advice

    Erik Baptist Erik Baptist
    Partner, Wiley Rein LLP

  24. Stakeholder panel: A look to the future

    Richard Engler Richard Engler
    Director of Chemistry, Bergeson & Campbell, PC
    Jeff Hafer Jeff Hafer
    Senior Regulatory Scientist, knoell USA, United States
    Erik Baptist Erik Baptist
    Partner, Wiley Rein LLP

  25. Q&A and conference wrap-up

    Chemical Watch

Back to top